eDetailing: Yesterday, Today and Tomorrow
... important information.” Another respondent was doubtful of the physician’s ability to do the job: “Physicians have enough to deal with today without spending their time and energy trying to explain and convince patients that brand A is really as good, has been around longer than, and is actually che ...
... important information.” Another respondent was doubtful of the physician’s ability to do the job: “Physicians have enough to deal with today without spending their time and energy trying to explain and convince patients that brand A is really as good, has been around longer than, and is actually che ...
Prescription Opioid Addiction:
... is dosed with naltrexone under heavy sedation or anesthesia. Naltrexone binds very strongly to opioid receptors but has none of the euphoric effects, effectively blocking receptors and causing almost instantaneous withdrawal. The entire procedure takes just 5 days, and patients report very little pa ...
... is dosed with naltrexone under heavy sedation or anesthesia. Naltrexone binds very strongly to opioid receptors but has none of the euphoric effects, effectively blocking receptors and causing almost instantaneous withdrawal. The entire procedure takes just 5 days, and patients report very little pa ...
New antiepileptic drugs
... new AEDs. Despite claims to the contrary, the safety profile of the new drugs is only slightly more favourable than that of the established drugs. The chronic side effect profile for the new drugs has also not yet been fully established. New AEDs marketed in the UK Eslicarbazepine acetate Eslicarbaz ...
... new AEDs. Despite claims to the contrary, the safety profile of the new drugs is only slightly more favourable than that of the established drugs. The chronic side effect profile for the new drugs has also not yet been fully established. New AEDs marketed in the UK Eslicarbazepine acetate Eslicarbaz ...
Advances in inflammatory bowel diseases 2012
... identified factors had a 15% risk of relapse within 1 year of discontinuing biologic therapy. A standard approach to this clinical challenge has not yet been defined, but this study certainly provides important information for our Crohn’s patients who discontinue their therapy. At the end of 2012, a ...
... identified factors had a 15% risk of relapse within 1 year of discontinuing biologic therapy. A standard approach to this clinical challenge has not yet been defined, but this study certainly provides important information for our Crohn’s patients who discontinue their therapy. At the end of 2012, a ...
Modulating tetracaine aggregation using nanoparticles to enhance topical administration Results and Discussion
... XJ Cai, P Mesquida, SA Jones ...
... XJ Cai, P Mesquida, SA Jones ...
Newer Therapies for Chronic Obstructive Pulmonary Disease
... Furthermore, LAMAs and LABAs have been shown to have synergistic effects.13,18 Since, these combinations are more likely to be used in severe or very severe COPD cases, addition of a steroid or anti-inflammatory drug would make sense, as steroids are likely to reduce the exacerbations in these patie ...
... Furthermore, LAMAs and LABAs have been shown to have synergistic effects.13,18 Since, these combinations are more likely to be used in severe or very severe COPD cases, addition of a steroid or anti-inflammatory drug would make sense, as steroids are likely to reduce the exacerbations in these patie ...
Traumatic brain injury: Current endeavours and trends for
... The compound is chemically affined to pyridoxine and penicillamine. It facilitates the passing of glucose across the bloodbrain barrier and increases its metabolism in neuronal tissue; also has antioxidant properties (44). Pyritinol is successfuly used as an immune-enhancer in rheumatoid arthritis ( ...
... The compound is chemically affined to pyridoxine and penicillamine. It facilitates the passing of glucose across the bloodbrain barrier and increases its metabolism in neuronal tissue; also has antioxidant properties (44). Pyritinol is successfuly used as an immune-enhancer in rheumatoid arthritis ( ...
Carbamazepine (Tegretol) Carbamazepine is one of the older drugs
... the treatment of epilepsy . It has a long history of effectiveness & safety . It is structurally similar to the tricyclic anti depressant agents . It has been the drug of choice for the treatment of trigeminal neuralgia & is used in treatment of generalised as well as complex partial seizures . It i ...
... the treatment of epilepsy . It has a long history of effectiveness & safety . It is structurally similar to the tricyclic anti depressant agents . It has been the drug of choice for the treatment of trigeminal neuralgia & is used in treatment of generalised as well as complex partial seizures . It i ...
Randomized Comparison Of Antiarrhythmic Drug Therapy With
... cardiac arrest, with a 2-year incidence between 20% and 45%1– 4; nonarrhythmic deaths account for the remaining fatalities. Several recent studies have provided evidence that class I antiarrhythmic drugs are less effective than class III drugs in patients with ventricular arrhythmias,5,6 most likely ...
... cardiac arrest, with a 2-year incidence between 20% and 45%1– 4; nonarrhythmic deaths account for the remaining fatalities. Several recent studies have provided evidence that class I antiarrhythmic drugs are less effective than class III drugs in patients with ventricular arrhythmias,5,6 most likely ...
April 2016 - Academy of Art University
... abnormally high level of activity or attention-deficit hyperactivity disorder (ADHD). It contains amphetamines and can be abused as a stimulant by those other than for whom prescribed. When abused, the tablets are either taken orally or crushed and snorted. Some abusers dissolve the tablets in water ...
... abnormally high level of activity or attention-deficit hyperactivity disorder (ADHD). It contains amphetamines and can be abused as a stimulant by those other than for whom prescribed. When abused, the tablets are either taken orally or crushed and snorted. Some abusers dissolve the tablets in water ...
ENHANCED SOLUBILIZATION OF AQUEOUS INSOLUBLE ANTI-HYPERTENSIVE DRUG Research Article
... is the most preferred form of drug delivery system in pharmaceutical technology, due to the ease of manufacturing, long shelf life, improved solubilization capacity and good thermodynamic stability. They are potential in improving the bioavailability of poorly water-soluble drugs by enhancing their ...
... is the most preferred form of drug delivery system in pharmaceutical technology, due to the ease of manufacturing, long shelf life, improved solubilization capacity and good thermodynamic stability. They are potential in improving the bioavailability of poorly water-soluble drugs by enhancing their ...
NWQA240_3_miconazole_gel_statins_interaction
... rosuvastatin undergoes limited metabolism by CYP2C9 and by CYP3A4 to a lesser extent [8]. Pravastatin is not metabolised to a clinically significant extent by the CYP450 system [9]. The Medicines and Healthcare products Regulatory Agency (MHRA) acknowledges the potential for interaction between som ...
... rosuvastatin undergoes limited metabolism by CYP2C9 and by CYP3A4 to a lesser extent [8]. Pravastatin is not metabolised to a clinically significant extent by the CYP450 system [9]. The Medicines and Healthcare products Regulatory Agency (MHRA) acknowledges the potential for interaction between som ...
IRTRA Combination Tablets LD/HD
... This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertaint ...
... This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertaint ...
Cytochrome P450 Drug Interactions Table
... While antidepressant medications are generally considered safe, they should be discontinued if they are not required. For first episodes of depression, it may be appropriate to discontinue medication after 4-9 months of continuation phase treatment since only 50% will have another episode of depress ...
... While antidepressant medications are generally considered safe, they should be discontinued if they are not required. For first episodes of depression, it may be appropriate to discontinue medication after 4-9 months of continuation phase treatment since only 50% will have another episode of depress ...
PDF
... Most of the cases described in the literature did not exhibit glaucoma antecedents (table I). The most important agent in this condition is ipratropio bromide, although AGAC cases have also been brought by salbutamol on its own. The incorrect application of the face mask and the high pharmacological ...
... Most of the cases described in the literature did not exhibit glaucoma antecedents (table I). The most important agent in this condition is ipratropio bromide, although AGAC cases have also been brought by salbutamol on its own. The incorrect application of the face mask and the high pharmacological ...
Re: Docket No. FDA-2015-N-0045 for International Drug Scheduling
... Substances Act. Consequently, it is strictly regulated, and safeguards are in place to prevent its illegal or unauthorized use. A change to this status would have deleterious impacts in clinical and research settings, where ketamine is approved as an anesthetic both for humans and animals. Ketamine ...
... Substances Act. Consequently, it is strictly regulated, and safeguards are in place to prevent its illegal or unauthorized use. A change to this status would have deleterious impacts in clinical and research settings, where ketamine is approved as an anesthetic both for humans and animals. Ketamine ...
FEC-D+TRAS Regimen - Cancer Care Ontario
... information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects o ...
... information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects o ...
Edarbyclor
... cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint Nat ...
... cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint Nat ...
Product Information - Therapeutic Goods Administration
... at final visit. The average sleep latencies (in minutes) in the MWT at baseline for the trials are shown in Table 1 below, along with the average change from baseline on the MWT at final visit. The percentages of patients who showed any degree of improvement on the CGI-C in the clinical trials are s ...
... at final visit. The average sleep latencies (in minutes) in the MWT at baseline for the trials are shown in Table 1 below, along with the average change from baseline on the MWT at final visit. The percentages of patients who showed any degree of improvement on the CGI-C in the clinical trials are s ...
FileList Convert a pdf file!
... 3. The HL B value of sodium lauryl su lphate is A) 6.5 B) 13.8 C) 25.0 D) 40.0 4. The d isintegration time for sugar coated tablet is A) 30 mins B) 45 mins C) 60 mins D) 75 mins 5. Antib iotic which interacts w ith ca lcium ion is A) Erythromycin B) Streptomycin C) Tetracyc line D) Ampic illin 6. Fl ...
... 3. The HL B value of sodium lauryl su lphate is A) 6.5 B) 13.8 C) 25.0 D) 40.0 4. The d isintegration time for sugar coated tablet is A) 30 mins B) 45 mins C) 60 mins D) 75 mins 5. Antib iotic which interacts w ith ca lcium ion is A) Erythromycin B) Streptomycin C) Tetracyc line D) Ampic illin 6. Fl ...
a review on dosage regimen - Indian Journal of Pharmaceutical
... also it helps in the prevention of unwanted effects of drugs, there are several methods to design the dosage regimen which are clearly mentioned in this article, In this paper, I review studies in which compliance was measured to determine the associations between dose frequency and medication compl ...
... also it helps in the prevention of unwanted effects of drugs, there are several methods to design the dosage regimen which are clearly mentioned in this article, In this paper, I review studies in which compliance was measured to determine the associations between dose frequency and medication compl ...
Switching from Kivexa to generic Abacavir/Lamivudine tablets
... When a drug company makes a new medicine, it is controlled under a patent. It has an approved, or generic name, as well as its own brand name, chosen by the company. For example ibuprofen is a generic name and Nurofen® is the brand name. Once the patent runs out, other drug companies can make the dr ...
... When a drug company makes a new medicine, it is controlled under a patent. It has an approved, or generic name, as well as its own brand name, chosen by the company. For example ibuprofen is a generic name and Nurofen® is the brand name. Once the patent runs out, other drug companies can make the dr ...
Word 40KB
... The PBAC considered the claim of superior comparative effectiveness of ulipristal over placebo was reasonable for the outcomes of controlling abnormal uterine bleeding and reducing both fibroid and uterine volume. The PBAC considered the claim of superior effectiveness was not adequately supported f ...
... The PBAC considered the claim of superior comparative effectiveness of ulipristal over placebo was reasonable for the outcomes of controlling abnormal uterine bleeding and reducing both fibroid and uterine volume. The PBAC considered the claim of superior effectiveness was not adequately supported f ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.